Union européenne - suédois - EMA (European Medicines Agency)

alnylam netherlands b.v. - patisiran natrium - amyloidos, familjär - andra nervsystemet droger - onpattro är indicerat för behandling av ärftligt transthyretin-medierad amyloidos (hattr amyloidos) hos vuxna patienter med steg 1 eller steg 2 polyneuropati.

Union européenne - suédois - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - denguefeber - vacciner - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 och 4. användning av dengvaxia bör ske i enlighet med officiella rekommendationer.

Union européenne - suédois - EMA (European Medicines Agency)

alnylam netherlands b.v. - givosiran - porphyrias, hepatisk - olika matsmältningsorgan och ämnesomsättning produkter - behandling av akut hepatisk porfyri (ahp) hos vuxna och ungdomar i åldern 12 år och äldre.

Union européenne - suédois - EMA (European Medicines Agency)

sanofi winthrop industrie - insulin aspart - diabetes mellitus - läkemedel som används vid diabetes - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Union européenne - suédois - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - multipelt myelom - antineoplastiska medel - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Union européenne - suédois - EMA (European Medicines Agency)

blueprint medicines (netherlands) b.v. - avapritinib - gastrointestinala stromaltumörer - andra antineoplastiska medel, protein kinas-hämmare - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

Union européenne - suédois - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningit, meningokock - vacciner - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.

Union européenne - suédois - EMA (European Medicines Agency)

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - influensa, människa - vacciner - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.

Union européenne - suédois - EMA (European Medicines Agency)

alnylam netherlands b.v. - lumasiran sodium - hyperoxaluria, primary - andra matsmältningsorgan och ämnesomsättning produkter, - treatment of primary hyperoxaluria type 1 (ph1) in all age groups.

Union européenne - suédois - EMA (European Medicines Agency)

seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastiska medel - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.